• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Rabies - Pipeline Review, H2 2012 Product Image

Rabies - Pipeline Review, H2 2012

  • ID: 2298912
  • October 2012
  • 63 pages
  • Global Markets Direct

Rabies – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Rabies - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Rabies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rabies.
- A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Rabies Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Rabies 9
Rabies Therapeutics under Development by Companies 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Rabies Therapeutics – Products under Development by Companies 17
Companies Involved in Rabies Therapeutics Development 18
Sanofi-Aventis 18
Celltrion, Inc. 19
Novavax, Inc. 20
Zydus Cadila Healthcare Limited 21
Crucell N.V. 22
Medicago Inc. 23
NanoViricides, Inc. 24
Lipoxen PLC 25
Kamada Ltd. 26
Sinovac Biotech Ltd. 27
Serum Institute of India Limited 28
Molecular Targeting Technologies, Inc. 29
Rabies – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Rabicide-I - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Human Rabies Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LipoRab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CL184 + Rabies Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Rabies VRVg - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Rabies VRVg - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CT-P19 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
KamRab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Purified Vero Cell Rabies Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SO-57 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Rabies VLP Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Verorab + Purified Equine Rabies Immunoglobulin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SOJB - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Vaccine For Rabies - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Rabies Therapeutics – Drug Profile Updates 54
Rabies Therapeutics - Dormant Products 55
Rabies – Product Development Milestones 56
Featured News & Press Releases 56
Aug 12, 2010: Zydus Joins WHO To Develop MAb Cocktail For Rabies 56
Jun 24, 2009: Crucell Announces Positive Results Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In Philippines 56
Jun 24, 2009: Crucell Presents Positive Phase II Study Results Of Rabies Monoclonal Antibody Combination At RITA Conference 57
Oct 01, 2008: Crucell Announces Positive Results Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In US 57
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 58
May 13, 2008: Crucell Initiates Phase II Clinical Study For Rabies Monoclonal Antibody Combination In The Philippines 58
Mar 31, 2008: Crucell Announces Start Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In US 59
Jan 03, 2008: Crucell Enters Agreement With Sanofi Pasteur For Next-generation Biologicals Against Rabies 59
Nov 30, 2007: Crucell Presents Positive Results Of Indian Phase I Rabies Antibody Cocktail Study 60
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products Under Development for Rabies, H2 2012 9
Products under Development for Rabies – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Sanofi-Aventis, H2 2012 18
Celltrion, Inc., H2 2012 19
Novavax, Inc., H2 2012 20
Zydus Cadila Healthcare Limited, H2 2012 21
Crucell N.V., H2 2012 22
Medicago Inc., H2 2012 23
NanoViricides, Inc., H2 2012 24
Lipoxen PLC, H2 2012 25
Kamada Ltd., H2 2012 26
Sinovac Biotech Ltd., H2 2012 27
Serum Institute of India Limited, H2 2012 28
Molecular Targeting Technologies, Inc., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Rabies Therapeutics – Drug Profile Updates 54
Rabies Therapeutics – Dormant Products 55

List of Figures
Number of Products under Development for Rabies, H2 2012 9
Products under Development for Rabies – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos